Abstract:Asparagine (Asn) deamidation and aspartic acid (Asp) isomerization are common degradation pathways that affect the stability of therapeutic antibodies. These modifications can pose a significant challenge in the development of biopharmaceuticals. As such, the early engineering and selection of chemically stable monoclonal antibodies (mAbs) can substantially mitigate the risk of subsequent failure. In this study, we introduce a novel in silico approach for predicting deamidation and isomerization sites in therapeutic antibodies by analyzing the structural environment surrounding asparagine and aspartate residues. The resulting quantitative structure-activity relationship (QSAR) model was trained using previously published forced degradation data from 57 clinical-stage mAbs. The predictive accuracy of the model was evaluated for four different states of the protein structure: (1) static homology models, (2) enhancing low-frequency vibrational modes during short molecular dynamics (MD) runs, (3) a combination of (2) with a protonation state reassignment, and (4) conventional full-atomistic MD simulations. The most effective QSAR model considered the accessible surface area (ASA) of the residue, the pKa value of the backbone amide, and the root mean square deviations of both the alpha carbon and the side chain. The accuracy was further enhanced by incorporating the QSAR model into a decision tree, which also includes empirical information about the sequential successor and the position in the protein. The resulting model has been implemented as a plugin named "Forecasting Reactivity of Isomerization and Deamidation in Antibodies" in MOE software, completed with a user-friendly graphical interface to facilitate its use.

What problem does this paper attempt to address?

This paper explores how to predict the positions of aspartate (Asn) deamidation and aspartate (Asp) isomerization in therapeutic antibodies, such as monoclonal antibodies (mAbs), which are common degradation pathways that affect antibody stability. The research team proposes a structure-based computational simulation method to predict these modification sites by analyzing the structural environment surrounding the aspartate and asparagine residues. They trained a quantitative structure-activity relationship (QSAR) model using previously published forced degradation data of 57 clinical-stage mAbs and evaluated the prediction accuracy under different protein structural states. In the study, the most effective QSAR model considered the solvent-accessible surface area of the residue, the pKa value of the backbone amide, and the root mean square deviation of the α carbon and side chain. By combining the QSAR model with a decision tree, the prediction accuracy was further improved. The decision tree also included experimental information about the subsequent amino acids in the sequence and the positions in the protein. The results were implemented as a plugin called "Forecasting Reactivity of Isomerization and Deamidation in Antibodies" integrated into the MOE software for user convenience. The paper points out that aspartate deamidation and isomerization pose challenges to the stability of biopharmaceuticals, and early engineering and selective chemical stabilization of mAbs can reduce the risk of development failure. In the study, the authors constructed a prediction model through screening and analysis of various molecular descriptors, achieving a balanced accuracy of 79% and 77% in predicting the risks of Asn deamidation and Asp isomerization in the CDR region, respectively. In conclusion, this paper aims to address the prediction of the occurrence sites of key degradation reactions in antibody drugs to support the development and optimization of antibody drugs.

Predicting deamidation and isomerization sites in therapeutic antibodies using structure-based in silico approaches

Accurate prediction of antibody deamidations by combining high-throughput automated peptide mapping and protein language model-based deep learning

The Accurate Prediction of Antibody Deamidations by Combining High-Throughput Automated Peptide Mapping and Protein Language Model-Based Deep Learning

Utility of High Resolution NMR Methods to Probe the Impact of Chemical Modifications on Higher Order Structure of Monoclonal Antibodies in Relation to Antigen Binding

Streamlined Multi-Attribute Assessment of an Array of Clinical-Stage Antibodies: Relationship Between Degradation and Stability

Modeling the impact of amino acid substitution in a monoclonal antibody on cation exchange chromatography

Using bispecific antibodies in forced degradation studies to analyze the structure-function relationships of symmetrically and asymmetrically modified antibodies

Multiscale modeling method for therapeutic antibodies in ion exchange chromatography

Steered molecular dynamics simulation as a post-process to optimize the iBRAB-designed Fab model

Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen

Automated optimisation of solubility and conformational stability of antibodies and proteins

Residue-resolved insights into the stabilization of therapeutic proteins by excipients: A case study of two monoclonal antibodies with arginine and glutamate

Predictive Model Building for Aggregation Kinetics Based on Molecular Dynamics Simulations of an Antibody Fragment

Assessment of chemical modifications of sites in the CDRs of recombinant antibodies

Comprehensive characterization of higher order structure changes in methionine oxidized monoclonal antibodies via NMR chemometric analysis and biophysical approaches

Prediction of immunogenicity for humanized and full human therapeutic antibodies

Molecular surface descriptors to predict antibody developability: sensitivity to parameters, structure models, and conformational sampling

Identification of Strategic Residues at the Interface of Antigen–Antibody Interactions by in Silico Mutagenesis

Optimization and kinetic modeling of interchain disulfide bond reoxidation of monoclonal antibodies in bioprocesses

A computational method for predicting the aggregation propensity of IgG1 and IgG4(P) mAbs in common storage buffers

Five computational developability guidelines for therapeutic antibody profiling